M. A. Ebert
Research Subjects
M. A. Ebert has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Georgiy I. Gafton
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - M. S. Sinyachkin
ФГБУ НМИЦ Онкологии им.Н.Н.Петрова
2 shared publications - Григорий Владимирович Зиновьев
ФГБУ НМИЦ онкологии имени Н.Н.Петрова Министерства здравоохранения Российской Федерации
2 shared publications - Иван Георгиевич Гафтон
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - A. B. Gogolev
Department of Cytopathology, Immunohistochemistry and Molecular Genetic Research, National Research Oncology Center, Astana, Kazakhstan
1 shared publication A. S. Mitrophanov
N. N. Petrov National Medical Research Oncology Center
1 shared publication
Latest Publications
- Open Access
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Vascular Reconstruction in Patients with Soft Tissue Sarcomas: Experience of N.N. Petrov National Medical Research Center of Oncology
Введение. Саркомы мягких тканей — редкая и гетерогенная группа опухолей. Инвазия в кровеносные сосуды описана в 5 % случаев сарком мягких тканей, что ранее было показанием к проведению калечащих операций. Благодаря внедрению различных методов пластической и реконструктивной хирургии, показания к конечность-сохраняющим операциям возрастают. Материалы и методы. 12 пациентов в период с 1 июня 2020 г. по 1 декабря 2024 г. получили лечение в НМИЦ онкологии им. Н.Н. Петрова с саркомами мягких тканей в объеме: удаление опухоли мягких тканей конечности с резекцией магистральных сосудов с реконструкцией артерии. Результаты. Операции выполнены на верхней конечности в 4 (33,3 %) случаях, на нижней конечности — в 8. В 6 случаях выполнена резекция только артерии, в 6 случаях — резекция артерии и вены, при этом восстановление целостности венозного русла не производилось. В 11 случаях для реконструкции сосудистого русла использовалась аутовена пораженной конечности, в 1 случае использована большая подкожна вена с контралатеральной конечности. Случаев тромбоза протезированной артерии, как в раннем послеоперационном периоде, так и при дальнейшем наблюдении за пациентами, не зафиксировано. Средний показатель по этой шкале составил 80 %, что соответствует хорошим результатам. Выводы. Вовлечение сосудистых структур не является абсолютным показанием для проведения калечащей операции при саркомах мягких тканей, но для оптимизации результатов лечения необходимо соответствующее планирование и определение тактики в условиях референсного центра.
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Open AccessVascular Reconstruction in Patients with Soft Tissue Sarcomas: Experience of N.N. Petrov National Medical Research Center of Oncology
Введение. Саркомы мягких тканей — редкая и гетерогенная группа опухолей. Инвазия в кровеносные сосуды описана в 5 % случаев сарком мягких тканей, что ранее было показанием к проведению калечащих операций. Благодаря внедрению различных методов пластической и реконструктивной хирургии, показания к конечность-сохраняющим операциям возрастают. Материалы и методы. 12 пациентов в период с 1 июня 2020 г. по 1 декабря 2024 г. получили лечение в НМИЦ онкологии им. Н.Н. Петрова с саркомами мягких тканей в объеме: удаление опухоли мягких тканей конечности с резекцией магистральных сосудов с реконструкцией артерии. Результаты. Операции выполнены на верхней конечности в 4 (33,3 %) случаях, на нижней конечности — в 8. В 6 случаях выполнена резекция только артерии, в 6 случаях — резекция артерии и вены, при этом восстановление целостности венозного русла не производилось. В 11 случаях для реконструкции сосудистого русла использовалась аутовена пораженной конечности, в 1 случае использована большая подкожна вена с контралатеральной конечности. Случаев тромбоза протезированной артерии, как в раннем послеоперационном периоде, так и при дальнейшем наблюдении за пациентами, не зафиксировано. Средний показатель по этой шкале составил 80 %, что соответствует хорошим результатам. Выводы. Вовлечение сосудистых структур не является абсолютным показанием для проведения калечащей операции при саркомах мягких тканей, но для оптимизации результатов лечения необходимо соответствующее планирование и определение тактики в условиях референсного центра.
- Open Access
- 7 July 2022
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 14 (2) , 36‑43
Pelvic endoprosthesis in tumor lesions: experience of N.N. Petrov National Medical Research Center of Oncology
Introduction. Oncological endoprosthesis for tumors of the pelvic bones is rare. It is associated with certain difficulties and is insufficiently investigated.The study objective is to evaluate the results of surgical treatment of patients with tumors of the pelvis performed between 2012 and 2021 at the N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included 23 patients with primary and secondary tumors of the pelvic bones who underwent limb-saving surgeries with substitution of the postresection defect with an endoprosthesis between 2012 and 2021. Mean follow-up duration was 19 months.Results. The most common postoperative complication was infection of the postoperative wound (n = 8; 35 %). Mechanical complications associated with the installed metallic prosthesis were observed in 4 (17 %) patients. Function al results were evaluated after 6 months using the Musculoskeletal Tumor Society Score (MSTS). Mean score per this scale was 53 % which corresponds to satisfactory outcome.Conclusion. Patients with malignant tumors of the pelvic bones should undergo treatment only in specialized medical facilities. Patients for organ-saving therapy should be carefully selected.
- 7 July 2022
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 14 (2) , 36‑43
Open AccessPelvic endoprosthesis in tumor lesions: experience of N.N. Petrov National Medical Research Center of Oncology
Introduction. Oncological endoprosthesis for tumors of the pelvic bones is rare. It is associated with certain difficulties and is insufficiently investigated.The study objective is to evaluate the results of surgical treatment of patients with tumors of the pelvis performed between 2012 and 2021 at the N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included 23 patients with primary and secondary tumors of the pelvic bones who underwent limb-saving surgeries with substitution of the postresection defect with an endoprosthesis between 2012 and 2021. Mean follow-up duration was 19 months.Results. The most common postoperative complication was infection of the postoperative wound (n = 8; 35 %). Mechanical complications associated with the installed metallic prosthesis were observed in 4 (17 %) patients. Function al results were evaluated after 6 months using the Musculoskeletal Tumor Society Score (MSTS). Mean score per this scale was 53 % which corresponds to satisfactory outcome.Conclusion. Patients with malignant tumors of the pelvic bones should undergo treatment only in specialized medical facilities. Patients for organ-saving therapy should be carefully selected.
- Open Access
- 1 November 2019
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 18 (5)
ADVANCED LARYNGEAL CANCER (LITERATURE REVIEW)
Background. Squamous carcinoma of the larynx is still the most common head and neck cancer in many Western countries. The larynx plays a key role for many essential functions, including breathing, voice production, airway protection, and swallowing. According to the world literature, 23,800 new cases of laryngeal cancer and 106,000 deaths from this disease are registered annually in the world. Laryngeal cancer treatment is aimed at achieving tumor control while optimizing functional outcomes.Objective: to review available data on surgical and non-surgical treatment options for locally advanced laryngeal cancer, as well as the evidence supporting each of these, including oncological outcomes (overall survival, disease-free survival, local control of the disease, functional outcomes and quality of life).Material and Methods. A systematic literature search was conducted in the electronic databases Medline, Cochrane Library, and Elibrary in the interval time between 1987 and 2016.Conclusions. In recent decades, the treatment paradigm for advanced laryngeal cancer has shifted from surgery (total laryngectomy) as the gold standard of treatment to nonsurgical organ-preserving treatment using radiation therapy or chemoradiation therapy. However, concerns have arisen regarding functional outcomes after chemoradiation therapy, as well as a possible reduction in overall survival in laryngeal cancer patients, risk factors, laryngectomy.
- 1 November 2019
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 18 (5)
Open AccessADVANCED LARYNGEAL CANCER (LITERATURE REVIEW)
Background. Squamous carcinoma of the larynx is still the most common head and neck cancer in many Western countries. The larynx plays a key role for many essential functions, including breathing, voice production, airway protection, and swallowing. According to the world literature, 23,800 new cases of laryngeal cancer and 106,000 deaths from this disease are registered annually in the world. Laryngeal cancer treatment is aimed at achieving tumor control while optimizing functional outcomes.Objective: to review available data on surgical and non-surgical treatment options for locally advanced laryngeal cancer, as well as the evidence supporting each of these, including oncological outcomes (overall survival, disease-free survival, local control of the disease, functional outcomes and quality of life).Material and Methods. A systematic literature search was conducted in the electronic databases Medline, Cochrane Library, and Elibrary in the interval time between 1987 and 2016.Conclusions. In recent decades, the treatment paradigm for advanced laryngeal cancer has shifted from surgery (total laryngectomy) as the gold standard of treatment to nonsurgical organ-preserving treatment using radiation therapy or chemoradiation therapy. However, concerns have arisen regarding functional outcomes after chemoradiation therapy, as well as a possible reduction in overall survival in laryngeal cancer patients, risk factors, laryngectomy.